We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current ARDS market cap is 44.57. The company's latest EPS is USD -0.6814 and P/E is 0.00.
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 2.76M | 1.02M | 1M | 1.54M | 3.09M |
| Operating Income | -24.16M | -30.04M | -22.41M | -42.71M | -29.99M |
| Net Income | -23.46M | -29.68M | -22.33M | -46.32M | -30.37M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 31.61M | 27.97M | 15.12M | 26.8M | 14.7M |
| Total Liabilities | 5.3M | 24.33M | 23.8M | 39.91M | 38.93M |
| Total Equity | 26.31M | 3.64M | -8.68M | -13.11M | -24.23M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -24.27M | -8.16M | -20.48M | -22.94M | -29.13M |
| Investing | -1.68M | -174k | -367k | -530k | -82k |
| Financing | 25.09M | 4.99M | 8.68M | 34.72M | 14.78M |
| Market Cap | 44.57 |
| Price to Earnings Ratio | 0.00 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 44.57M |
| Average Volume (1 week) | 7.1k |
| Average Volume (1 Month) | 17.25k |
| 52 Week Change | -100.00% |
| 52 Week High | 0.0945 |
| 52 Week Low | 0.000001 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Aridis Pharmaceuticals Inc (CE) |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.aridispharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
